Filing identity and reporting period
The supplied filing is Rosewind Corporation’s Form 10-K for the fiscal year ended August 31, 2013—not an AYTU Biopharma filing or a 2012 Q4 report. The filing describes Rosewind as a development-stage sailing-school business. Its financial statements were audited and received an unqualified opinion, with a going-concern emphasis.
Financial results and liquidity
- Fiscal 2013 revenue was $1,750, unchanged from fiscal 2012; reported revenue since inception was $5,250. The company reported only minimal student training activity.
- Net loss was $57,318, versus $59,675 in fiscal 2012, a decrease of $2,357 (about 4%). Basic and diluted loss per share were $0.01 in both years.
- Operating expenses were $54,164, compared with $58,106. Professional fees rose to $18,080 from $17,186; general and administrative expenses fell to $29,904 from $33,580. Interest expense increased to $4,904 from $3,319.
- Cash used in operations was $37,704, versus $37,849. Financing provided $39,457, primarily including $31,457 in related-party loans; year-end cash was $1,862, up from $109.
- At August 31, 2013, total assets were $9,669, current liabilities were $120,525, and the working-capital deficit was $118,663. Related-party loans payable were $99,510, with $13,373 of accrued interest. The loan bears 6% interest and is secured by the vessel.
- Shareholders’ deficit was $110,856. The filing reports accumulated development-stage losses of $568,204. No meaningful operating margin is indicated given the very small revenue base and continuing losses.
Changes, outlook, and key risks
- Management attributed the lower annual loss mainly to reduced general and administrative costs; revenue was unchanged year over year. Cash remained extremely limited despite additional related-party borrowing.
- Management’s model estimates positive quarterly cash flow if it sells and completes six one-week voyages per quarter, with two students per voyage. The filing gives no assurance this booking level can be reached; marketing had produced disappointing results.
- The company planned to continue advertising and seek additional equity funding. Management stated there was no assurance it could raise funds. The auditor and management cited substantial doubt about the company’s ability to continue as a going concern.
- Key risks include inadequate cash and ongoing public-company costs (estimated by management at more than $25,000 annually), limited demand, vessel maintenance and weather-related disruptions, regulatory and tax uncertainties, and limited insurance. The vessel had liability coverage but no hull insurance; disclosed coverage included $100,000 watercraft liability and $1,000 medical payments per person.
- The company had one employee and one director/officer, James B. Wiegand, who also performed operational functions. The filing discloses related-party borrowing and contributed services, as well as potential conflicts of interest.
- An $800 California annual business expense was included as an allowance; a disputed Alameda County personal-property tax assessment remained unresolved. The filing states there was no pending or threatened litigation or regulatory proceeding.
Important facts to verify
- Confirm the issuer and period: the supplied content is Rosewind Corporation’s FY2013 10-K, inconsistent with the AYTU Biopharma and 2012 Q4 request metadata.
- Reconcile the filing’s descriptions of student counts and voyages; the narrative includes inconsistent counts, while reported fiscal-year revenue is $1,750 for each of the last two years.
- Review the related-party loan balance, maturity terms, accrued interest, and any subsequent repayment or extension.
- Assess near-term funding needs, the status of equity-raising efforts, and the company’s ability to meet current liabilities and public-company costs.
- Check the status of operating permissions, insurance applications, and the disputed California property-tax assessment.